Condition: Multiple Myeloma · Sponsor: Hackensack Meridian Health
This phase I study utilizes a 3+3 design with escalating cohorts of Carfilzomib at 20mg/m2, 27mg/m2, 36mg/m2, 45mg/m2, 56mg/m2, and 70mg/m2 to be administered concomitantly with Cyclophosphamide 2 gm/m2, Dexamethasone and Granulocyte colony-stimulating factor (G-CSF)
This description comes directly from the study's public registry record.
Mariefel Vendivil · 551-996-5828 · Mariefel.Vendivil@hmhn.org
Geneva Khan · 551-996-3923 · Geneva.Khan@hmhn.org
Always discuss trial participation with your own doctor first.
| Hackensack Meridian Health - John Theurer Cancer Center | Hackensack, New Jersey, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03909412